T. Rowe Price Associates’s Mersana Therapeutics MRSN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-62,093
| Closed | -$22K | – | 3114 |
|
|
2025
Q1 | $22K | Hold |
62,093
| – | – | ﹤0.01% | 2999 |
|
|
2024
Q4 | $89K | Sell |
62,093
-36,985
| -37% | -$53K | ﹤0.01% | 2845 |
|
|
2024
Q3 | $188K | Hold |
99,078
| – | – | ﹤0.01% | 2667 |
|
|
2024
Q2 | $200K | Buy |
99,078
+19,146
| +24% | +$38.6K | ﹤0.01% | 2593 |
|
|
2024
Q1 | $359K | Buy |
79,932
+4,962
| +7% | +$22.3K | ﹤0.01% | 2348 |
|
|
2023
Q4 | $174K | Sell |
74,970
-12,143
| -14% | -$28.2K | ﹤0.01% | 2587 |
|
|
2023
Q3 | $111K | Sell |
87,113
-32,232
| -27% | -$41.1K | ﹤0.01% | 2637 |
|
|
2023
Q2 | $394K | Sell |
119,345
-2,032
| -2% | -$6.71K | ﹤0.01% | 2238 |
|
|
2023
Q1 | $500K | Buy |
121,377
+858
| +0.7% | +$3.53K | ﹤0.01% | 2105 |
|
|
2022
Q4 | $707K | Buy |
120,519
+8,480
| +8% | +$49.7K | ﹤0.01% | 1967 |
|
|
2022
Q3 | $758K | Sell |
112,039
-27,780
| -20% | -$188K | ﹤0.01% | 1906 |
|
|
2022
Q2 | $646K | Buy |
139,819
+1,785
| +1% | +$8.25K | ﹤0.01% | 2100 |
|
|
2022
Q1 | $551K | Buy |
138,034
+23,587
| +21% | +$94.2K | ﹤0.01% | 2284 |
|
|
2021
Q4 | $712K | Sell |
114,447
-866,449
| -88% | -$5.39M | ﹤0.01% | 2208 |
|
|
2021
Q3 | $9.25M | Sell |
980,896
-1,336,851
| -58% | -$12.6M | ﹤0.01% | 1427 |
|
|
2021
Q2 | $31.5M | Sell |
2,317,747
-656,340
| -22% | -$8.91M | ﹤0.01% | 1180 |
|
|
2021
Q1 | $48.1M | Sell |
2,974,087
-330,259
| -10% | -$5.34M | ﹤0.01% | 1014 |
|
|
2020
Q4 | $87.9M | Buy |
3,304,346
+1,475,727
| +81% | +$39.3M | 0.01% | 769 |
|
|
2020
Q3 | $34M | Buy |
1,828,619
+1,083,399
| +145% | +$20.2M | ﹤0.01% | 999 |
|
|
2020
Q2 | $17.4M | Buy |
+745,220
| New | +$17.4M | ﹤0.01% | 1179 |
|